Humabiologics GMP hydrogels are now ISO 13485 certified

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

The Humabiologics human-derived hydrogels for regenerative medicine are now ISO 13485:2016 certified as well as GMP compliant for the manufacturing of human-derived biomaterials. The scope of the certificate covers the design, manufacture, and distribution of human biomaterials, components, and sub-assemblies for use in research and development, medical devices, pharmaceuticals, and biologic products.

The ISO 13485:2016 registration positions Humabiologics among the first global providers of GMP (Good Manufacturing Practices) grade human-derived biomaterials to support and expedite the future development of human regenerative therapies and tissue models for drug discovery through clinically relevant high-quality products.

Humabiologics GMP hydrogels are now ISO 13485 certifiedHumabiologics is a regenerative medicine company founded by scientists and tissue industry experts focused on narrowing the gap between the gift of donated human tissues and researchers by providing human-derived biomaterials. The company develops and commercializes high-quality, affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, and drug screening.

Recently, Humabiologics introduced the world’s first native human collagen and gelatin-based bioinks. By becoming ISO 13485:2016 registered, Humabiologics has proven its ability to manufacture these biomaterial hydrogels under strict regulatory conditions including those required under the FDA’s Good Manufacturing Practices (GMP).

“We are excited to continue our mission of providing clinically-relevant human-derived biomaterials under our GMP compliant ISO 13485 registered quality system to support our customers and partners for the development of regenerative human therapies and drug discovery”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics.“

As the field is accelerating towards creating human organs and tissues and paving the way to eliminate the use of unreliable animal models for drug discovery, we remain focused on consistently providing high-quality products to standardize these research endeavors around the world and reduce the time and cost that is needed to develop innovative personalized human therapies.

Research 2022
Polymer AM Market Opportunities and Trends

741 unique polymer AM companies individually surveyed and studied. Core polymer AM market generated $4.6 billion...

Davide Sher

Since 2002, Davide has built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, he spent 12 years in the United States, where he completed his studies at SUNY USB. As a journalist covering the tech and videogame industry for over 10 years, he began covering the AM industry in 2013, first as an international journalist and subsequently as a market analyst, focusing on the additive manufacturing industry and relative vertical markets. In 2016 he co-founded London-based 3dpbm. Today the company publishes the leading news and insights websites 3D Printing Media Network and Replicatore, as well as 3D Printing Business Directory, the largest global directory of companies in the additive manufacturing industry.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*